Aarti Industries Ltd. expects its revenue to grow 15-20 percent in financial year 2019-20, aided by growth in its pharmaceutical business.
“Performance in financial year ending 2020 also depends on how the anticipated disruption from Chinese players pans out,” Rajendra V Gogri, its chairman & managing director, told BloombergQuint. “Also, like this year, pharma segment will continue to be one of the major participants in the growth.”
Gogri said the impact of the three long-term contracts will start kicking in from financial year 2020-21.
Key Highlights (YoY)
- Revenue up 18 percent to Rs 1,211 crore.
- Net profit up 46.5 percent to Rs 124.5 crore.
- Ebitda up 31 percent to Rs 236.5 crore.
- Margins at 19.5 percent versus 17.5 percent.
Shares of the company fell 4.2 percent to close at Rs 1,645.35 apiece compared with a 0.25 percent gain in the Nifty Index.
Watch the full interview here:
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
